ArticleCurrent infectious disease reports2013
Endemic mycoses in immunocompromised hosts.
Article in Current infectious disease reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing.Microbiology spectrum · 2025Trial
- Mapping the Landscape of Endemic Mycoses in India: Insights From a Systematic Review of Reported Cases Spanning 6 Decades (1960-2025).Open forum infectious diseases · 2026Article
- Fungal sepsis in a 7-month-old female: diagnosis through peripheral blood smear.Medical mycology case reports · 2025Article
- Navigating Trichosporon Asahii Infections in Pediatric Leukemia: First Reported Case in Central and Eastern Europe Case Report and Literature Review.Infection and drug resistance · 2025Article
- Clinico-Demographic Parameters of Oral Fungal Infections: An Institutional Retrospective Study.Cureus · 2024Article
- Ketoconazole induces reversible antifungal drug tolerance mediated by trisomy of chromosome R inFrontiers in microbiology · 2024Article
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.Infection and drug resistance · 2024Review
- Parallel evolution of fluconazole resistance and tolerance inFrontiers in cellular and infection microbiology · 2024Article
- Diagnosis of invasive fungal infections: challenges and recent developments.Journal of biomedical science · 2023Review
- Endemic mycoses in children in North America: a review of radiologic findings.Pediatric radiology · 2023Review
- Impact of diet and host genetics on the murine intestinal mycobiome.Nature communications · 2023Article
- Comparison of Indirect Fungal Diagnostic Tests in Patients With Proven Histoplasmosis.Open forum infectious diseases · 2022Article
- Endemic mycoses in South Africa, 2010-2020: A decade-long description of laboratory-diagnosed cases and prospects for the future.PLoS neglected tropical diseases · 2022Article
- Allicin as a Volatile or Nebulisable Antimycotic for the Treatment of Pulmonary Mycoses: In Vitro Studies Using a Lung Flow Test Rig.International journal of molecular sciences · 2022Article
- Editorial: Fungal cell wall proteins with functions in cell wall biogenesis, cell wall signaling and interactions with host.Frontiers in cellular and infection microbiology · 2022Article
- Future Directions for Clinical Respiratory Fungal Research.Mycopathologia · 2021Review
- Diagnosis of Pneumonia Due to Invasive Molds.Diagnostics (Basel, Switzerland) · 2021Review
- Fungal evolution: major ecological adaptations and evolutionary transitions.Biological reviews of the Cambridge Philosophical Society · 2019Review
- Pathogenic Fungal Infection in the Lung.Frontiers in immunology · 2019Review
- Oxygen-responsive transcriptional regulation of lipid homeostasis in fungi: Implications for anti-fungal drug development.Seminars in cell & developmental biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Endemic mycoses remain a significant cause of morbidity and mortality among immunocompromised patients. As the number of immunosuppressed individuals increases worldwide, the incidence of endemic mycoses is also expected to rise. In immunocompromised patients, endemic mycoses can present in atypical fashion, cause more severe and/or disseminated disease, and result in higher mortality. Despite several noteworthy advances over the past decade, significant challenges remain with regard to the prevention, diagnosis, and therapy of endemic mycoses in immunocompromised hosts. This review highlights important developments related to the epidemiology, diagnosis, treatment, and prevention of commonly encountered endemic mycoses. We also discuss emerging topics, knowledge gaps, and areas of future research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.